跳至主導覽
跳至搜尋
跳過主要內容
長庚大學學術能量集萃 首頁
說明與常見問題
!!Link opens in a new tab
English
中文
在 長庚大學學術能量集萃 搜尋內容
首頁
學者概覽
研究單位
研究產出
研究計畫-專案
獎項
活動
新聞/媒體
設備
查看斯高帕斯 (Scopus) 概要
陳 志根
臨床教授
,
醫學系
電子郵件
D000001420
cgu.edu
tw
h-index
h10-index
h5-index
4006
引文
33
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
824
引文
18
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
313
引文
9
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
1998 …
2026
每年研究產出
概覽
指紋
網絡
研究計畫-專案
(16)
研究產出
(147)
相近領域學者
(6)
指紋
查看啟用 Chih-Ken Chen 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Psychology
Adolescents
13%
Alcohol
12%
Anxiety
19%
Assessment
29%
Attention
23%
Attention Deficit
77%
Behavior
30%
Bipolar Disorder
33%
Children
23%
Clinical Interview
10%
Cognition
15%
Cognitive Behavioral Therapy
9%
Cognitive Decline
11%
Cognitive Performance
7%
Comorbidity
18%
Cortisol
6%
Dehydroepiandrosterone
18%
Depression
49%
Depression
7%
Depression Scale
14%
Dopamine
23%
Gender Difference
13%
Groups
47%
Hazard Ratio
6%
Health
14%
I-Disorder
16%
Interviews
36%
Kidney Disease
7%
Major Depression
13%
Meta-Analysis
14%
Methylphenidate
32%
Mood
14%
Mood Disorder
11%
Obesity
7%
Patient with Attention Deficit Hyperactivity Disorder
13%
Prevention Program
9%
Processing Speed
7%
Psychiatric Disorder
18%
Psychometrics
7%
Psychotic Disorder
12%
Quality of Life
13%
Questionnaires
8%
Rating Scale
17%
Reaction Time
7%
Reliability
8%
Schizoaffective Disorder
9%
Schizophrenia
50%
Teachers
6%
Treatment
77%
Validity
7%
Medicine and Dentistry
Adolescent
9%
Age
14%
Analysis
14%
Anxiety
12%
Anxiety Disorder
9%
Association
30%
Attention Deficit Disorder
31%
Bipolar Disorder
29%
Bipolar I Disorder
10%
Chemotherapeutic Agent
19%
Chronic Kidney Disease
18%
Cognition
14%
Diagnosis
18%
Disease
13%
Drug
19%
Drug Use
16%
Family
10%
Follow up
15%
Gene
12%
Hemodialysis
18%
Hospital
11%
Hospital Anxiety and Depression Scale
10%
Illicit Drug
13%
Infection
10%
Inpatient
37%
Ketamine
18%
Lithium
9%
Major Depressive Episode
19%
Male
14%
Mental Health
10%
Meta-Analysis
14%
Methamphetamine
31%
Methylphenidate
14%
Mood Disorder
9%
Mood Stabilizer
10%
Odds Ratio
11%
Olanzapine
9%
Patient
100%
Patient with Attention Deficit Hyperactivity Disorder
9%
Psychoactive Drug
15%
Psychosis
29%
Psychosis
13%
Quality of Life
10%
Screening
10%
Sex Difference
9%
Symptom
35%
Systematic Review
9%
Therapeutic Procedure
50%
Typical Antipsychotic
9%
Young Adult
9%
Neuroscience
5-HTTLPR
7%
Antipsychotic
14%
Anxiety
13%
Aripiprazole
22%
Attention
15%
Attention Deficit Hyperactivity Disorder
72%
Behavior (Neuroscience)
13%
Bipolar Disorder
47%
Bipolar I Disorder
20%
Brain
6%
Brain-Derived Neurotrophic Factor
18%
Cognition
15%
Cognitive Disorders
10%
Comorbidity
5%
Dehydroepiandrosterone
9%
Dehydroepiandrosterone Sulfate
9%
Dementia Praecox
27%
Depression
43%
DNA Polymorphism
9%
Dopamine
12%
Dopamine Transporter
9%
Gene
46%
Genotype
9%
Glutamic Acid
6%
Haplotype
17%
Hyperactivity
6%
Ketamine
37%
Lithium
11%
Major Depressive Disorder
18%
Methamphetamine
48%
Methamphetamine-Induced Psychosis
9%
Methylphenidate
27%
Mood Stabilizer
11%
Olanzapine
16%
Physical Dependence
7%
Polymorphism
42%
Primary Insomnia
6%
Promoter Region
8%
Psychiatry
6%
Psychosis
21%
Schizoaffective Disorder
9%
Schizophrenia Spectrum Disorder
6%
Serotonin Transporter
14%
Single-Nucleotide Polymorphism
6%
Sleep
9%
Subjective Cognitive Decline
18%
Synapsin I
11%
Test of Variables of Attention
8%
Untranslated Region
7%
Variable Number Tandem Repeat
10%
